Annual Report

Overview

The report highlights Curatis Group's 2025 revenue growth to CHF 10.8 million and reduction of its loss to CHF 1.4 million. It describes a successful September 2025 FDA meeting that validated plans for a pivotal Phase 3 corticorelin study. It also records the March 2026 exclusive Japanese licensing deal with Neupharma and continued expansion of the company's development and distribution activities.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services